HKSE - Delayed Quote HKD

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

15.260 -0.620 (-3.90%)

At close: October 30 at 4:08:06 PM GMT+8

Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma

GlobeNewswire 2d ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

GlobeNewswire 3d ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

GlobeNewswire 4d ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

GlobeNewswire 8d ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

GlobeNewswire 2mo ago

1877.HK
-3.90%
688180.SS
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

GlobeNewswire 3mo ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)

GlobeNewswire 3mo ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

GlobeNewswire 5mo ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

GlobeNewswire 5mo ago

688180.SS

688331.SS

1877.HK
-3.90%
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

GlobeNewswire 6mo ago

688180.SS

1877.HK
-3.90%
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

GlobeNewswire 10mo ago

SHJBF

U.S. markets closed

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis